These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients. Wareham NE; Mocroft A; Sengeløv H; Da Cunha-Bang C; Gustafsson F; Heilmann C; Iversen M; Kirkby NS; Rasmussen A; Sørensen SS; Lundgren JD; J Cancer Res Clin Oncol; 2018 Aug; 144(8):1569-1580. PubMed ID: 29804164 [TBL] [Abstract][Full Text] [Related]
23. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders. Dolcetti R Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317 [TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus lymphoproliferative disease after solid organ transplantation. Prockop SE; Vatsayan A Cytotherapy; 2017 Nov; 19(11):1270-1283. PubMed ID: 28965834 [TBL] [Abstract][Full Text] [Related]
25. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases. Babel N; Gabdrakhmanova L; Hammer M; Rosenberger C; Oppert M; Volk HD; Reinke P Transpl Infect Dis; 2005; 7(3-4):133-6. PubMed ID: 16390402 [TBL] [Abstract][Full Text] [Related]
26. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Gulley ML; Swinnen LJ; Plaisance KT; Schnell C; Grogan TM; Schneider BG; Transplantation; 2003 Sep; 76(6):959-64. PubMed ID: 14508361 [TBL] [Abstract][Full Text] [Related]
27. Evidence of Epstein-Barr virus heterogeneous gene expression in adult lung transplant recipients with posttransplant lymphoproliferative disorder. Zaffiri L; Frankel C; Bush EJ; Neely ML; Pavlisko EN; Mokrova IL; Luftig MA; Palmer SM J Med Virol; 2021 Aug; 93(8):5040-5047. PubMed ID: 33704812 [TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus-DNA load monitoring late after lung transplantation: a surrogate marker of the degree of immunosuppression and a safe guide to reduce immunosuppression. Bakker NA; Verschuuren EA; Erasmus ME; Hepkema BG; Veeger NJ; Kallenberg CG; van der Bij W Transplantation; 2007 Feb; 83(4):433-8. PubMed ID: 17318076 [TBL] [Abstract][Full Text] [Related]
31. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761 [TBL] [Abstract][Full Text] [Related]
32. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Riddler SA; Breinig MC; McKnight JL Blood; 1994 Aug; 84(3):972-84. PubMed ID: 8043879 [TBL] [Abstract][Full Text] [Related]
34. Late Persistent Positive EBV Viral Load and Risk of Solid Cancer in Kidney Transplant Patients. Bamoulid J; Courivaud C; Coaquette A; Crépin T; Carron C; Gaiffe E; Roubiou C; Rebibou JM; Ducloux D Transplantation; 2017 Jun; 101(6):1473-1478. PubMed ID: 27367471 [TBL] [Abstract][Full Text] [Related]
35. Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder. Sen A; Enriquez J; Rao M; Glass M; Balachandran Y; Syed S; Twist CJ; Weinberg K; Boyd SD; Bernstein D; Trickey AW; Gratzinger D; Tan B; Lapasaran MG; Robien MA; Brown M; Armstrong B; Desai D; Mazariegos G; Chin C; Fishbein TM; Venick RS; Tekin A; Zimmermann H; Trappe RU; Anagnostopoulos I; Esquivel CO; Martinez OM; Krams SM Front Immunol; 2022; 13():994552. PubMed ID: 36304469 [TBL] [Abstract][Full Text] [Related]
36. Interferon-alpha and its effects on post-transplant lymphoproliferative disorders. Faro A Springer Semin Immunopathol; 1998; 20(3-4):425-36. PubMed ID: 9870255 [TBL] [Abstract][Full Text] [Related]
37. Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients. Wistinghausen B; Gross TG; Bollard C Pediatr Hematol Oncol; 2013 Sep; 30(6):520-31. PubMed ID: 23802715 [TBL] [Abstract][Full Text] [Related]
38. Utility of semiquantitative polymerase chain reaction for Epstein-Barr virus to measure virus load in pediatric organ transplant recipients with and without posttransplant lymphoproliferative disease. Allen U; Hebert D; Petric M; Tellier R; Tran D; Superina R; Stephens D; West L; Wasfy S; Nelson S Clin Infect Dis; 2001 Jul; 33(2):145-50. PubMed ID: 11418872 [TBL] [Abstract][Full Text] [Related]
39. Epstein-Barr virus (EBV)-positive lymphoproliferations in post-transplant patients show immunoglobulin V gene mutation patterns suggesting interference of EBV with normal B cell differentiation processes. Bräuninger A; Spieker T; Mottok A; Baur AS; Küppers R; Hansmann ML Eur J Immunol; 2003 Jun; 33(6):1593-602. PubMed ID: 12778477 [TBL] [Abstract][Full Text] [Related]
40. Impact of Epstein-Barr virus in monomorphic B-cell posttransplant lymphoproliferative disorders: a histogenetic study. Johnson LR; Nalesnik MA; Swerdlow SH Am J Surg Pathol; 2006 Dec; 30(12):1604-12. PubMed ID: 17122518 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]